6/28/23, 10:40 PM FOURIER Pathway Feedback Search Clinical Topics Home Studies FOURIER FOURIER Disease Disease Coronary artery disease Dyslipidemia Trial question What is the role of evolocumab in patients with ASCVD and LDL cholesterol levels 70 mg/dL who were receiving statin therapy? Study design Multi-center Double blinded RCT Population Characteristics of study participants 25.0% female N = 27564 75.0% male 27564 patients (6769 female, 20795 male) Inclusion criteria: patients with ASCVD and LDL cholesterol 70 mg/dL (1.8 mmol/L) who were receiving statin therapy Key exclusion criteria: known hemorrhagic stroke, uncontrolled or recurrent VT, uncontrolled hypertension, planned or expected cardiac surgery or revascularization within 3 months, severe renal dysfunction, pregnant or breastfeeding women Interventions N=13784 evolocumab (either 140 mg every 2 weeks or 420 mg monthly SC) N=13780 placebo (subcutaneous injections) Primary outcome Major cardiovascular events 11.3 % 11.3 https://web.pathway.md/studies/recTB7IuvQL1jb5rb 1/2 6/28/23, 10:40 PM FOURIER Pathway 9.8 8.5 % 5.7 % Significant decrease 2.8 % NNT = 67 0.0 % Evolocumab Placebo Significant decrease in major cardiovascular events (9.8% vs. 11.3%; HR 0.85, 95% CI 0.79 to 0.92) Secondary outcomes Significant decrease in cardiovascular death, myocardial infarction, or stroke (5.9% vs. 7.4%; HR 0.8, 95% CI 0.73 to 0.88) Safety outcomes No significant differences in overall adverse events, with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). Conclusion In patients with ASCVD and LDL cholesterol 70 mg/dL (1.8 mmol/L) who were receiving statin therapy, evolocumab was superior to placebo with respect to major cardiovascular events. Reference Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. Open reference URL https://web.pathway.md/studies/recTB7IuvQL1jb5rb 2/2